Guggenheim upgraded Travere Therapeutics to Buy from Neutral with a $25 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Broadcom AI results fail to enthuse the Street: Morning Buzz
- Travere Therapeutics price target raised to $23 from $14 at Citi
- Ligand, Travere Therapeutics receives full FDA approval for Filspari
- Travere Therapeutics price target raised to $19 from $18 at BofA
- Travere Therapeutics price target raised to $23 from $20 at H.C. Wainwright